|
||
|
AEROVANCE, INC
Download PDF Members: Aerovance is a privately held biopharmaceutical company exclusively focused on developing and commercializing biotherapeutics. The company maintains a solid intellectual property position with its strong portfolio of potential breakthrough products now in clinical development and several pre-clinical programs. The lead products are human recombinant proteins: AEROVANT™, an IL-4 and IL-13 receptor antagonist currently in Phase 2a studies for asthma; AEROLYTIC™, a serine protease inhibitor in Phase 2a for Cystic Fibrosis; AERODERM™, an IL-4 and IL-13 receptor antagonist in Phase 2a for eczema, and PULMOLYTIC™, a serine protease inhibitor in Phase 2a for COPD.
This page has been viewed 290 times since April 2007, the link to the organisation's website has been followed 44 times Recent Search Terms used to find this page: t | aerovance | pulmolytic | Aerovance- Business Development | Aerovance Inc Berkeley | aerolytic phase 2a | AEROVANCE inc | Pulmolytic for COPD | . Search for more companies in Berkeley Search for more companies in California This site uses Thumbshots previews, resources from the NCBI applied. Maps are centred on zip/postcodes and should not be relied upon for exact building locations. Some information on this page has been collected automatically and may not have been verified. BioPortfolio search results for AEROVANCE, INC | ||||||||||||||||||||||||||||||||||||||
Nothing in this website should be used in place of personal medical
advice from your own qualified medical practitioner. See
User
Agreement |
All rights reserved. All other trademarks recognized. |
|
|